Grace Therapeutics, Inc.
$4.59
▲
5.12%
2026-04-21 07:10:01
www.gracetx.com
NCM: GRCE
Explore Grace Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$71.03 M
Current Price
$4.59
52W High / Low
$5.18 / $2
Stock P/E
—
Book Value
$4.19
Dividend Yield
—
ROCE
-23.81%
ROE
-10.22%
Face Value
—
EPS
$-0.31
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
6
Beta
0.69
Debt / Equity
—
Current Ratio
14.96
Quick Ratio
11.77
Forward P/E
-5.64
Price / Sales
—
Enterprise Value
$36.88 M
EV / EBITDA
-3.28
EV / Revenue
—
Rating
None
Target Price
$11.35
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Keros Therapeutics, Inc. | $11.66 | 2.64 | $230.1 M | — | 21.27% | 19.9% | $22.55 / $10.41 | $15.51 |
| 2. | Cardiff Oncology, Inc. | $1.78 | — | $123.06 M | — | -107.63% | -71.45% | $4.55 / $1.48 | $0.66 |
| 3. | Precision BioSciences, Inc. | $7.58 | — | $187.43 M | — | -35.84% | -62.71% | $8.82 / $3.53 | $3.83 |
| 4. | Corcept Therapeutics Incorporated | $46.34 | 49.18 | $4.9 B | — | 6.68% | 15.02% | $91 / $28.66 | $6.11 |
| 5. | Maze Therapeutics, Inc. | $26.84 | — | $1.4 B | — | -38.15% | -47.52% | $53.65 / $7.16 | $7.2 |
| 6. | Pharvaris N.V. | $28.97 | — | $1.86 B | — | -54.28% | -65.19% | $29.89 / $13.6 | $5.56 |
| 7. | Curanex Pharmaceuticals Inc | $0.48 | — | $12.79 M | — | -37.04% | -85.25% | $9.18 / $0.26 | $0.01 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.45 M | -2.53 M | -3.09 M | -3.18 M | -3.7 M | — |
| Net Profit | -2.31 M | -0.94 M | -3.36 M | 0.64 M | -4.16 M | — |
| EPS in Rs | -0.15 | -0.06 | -0.22 | 0.04 | -0.27 | -0.3 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -16.68 M | -11.37 M | -18.25 M | -15.34 M |
| Net Profit | -9.57 M | -12.85 M | -42.43 M | -9.82 M |
| EPS in Rs | -0.62 | -0.83 | -2.74 | -0.63 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 71.99 M | 73.3 M | 79.12 M | 128.62 M |
| Total Liabilities | 5.38 M | 11.56 M | 11.17 M | 20.35 M |
| Equity | 66.61 M | 61.74 M | 67.95 M | 108.27 M |
| Current Assets | 22.71 M | 24.01 M | 29.29 M | 45.28 M |
| Current Liabilities | 1.93 M | 1.68 M | 3.41 M | 3.26 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -14.9 M | -12.33 M | -15.91 M | -17.23 M |
| Investing CF | 0 M | 0.1 M | 13.15 M | -3.52 M |
| Financing CF | 14.03 M | 7.36 M | 0.3 M | 0 M |
| Free CF | -14.9 M | -12.36 M | -15.93 M | -17.23 M |
| Capex | — | -0.02 M | -0.02 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 25.56% | 69.71% | -332.11% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-07-10 | 1:0.166667 |
| 2021-08-31 | 1:0.125 |